Clasificación en acciones
#41904
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition,... Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$7.87K
Comercio Biostax Corp. (BTAX)
Número de acciones en circulación de Biostax Corp. (BTAX)
Número de acciones en circulación al August 2026: 0
Según los últimos informes financieros y el precio de las acciones de Biostax Corp., el número actual de acciones en circulación es 0. Al final de August 2026, la empresa tenía 0 acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Biostax Corp. (BTAX) desde 2026 hasta 2026
Acciones en circulación al final de cada año
| Año |
Acciones en circulación |
Cambiar |
|
Not enough data for the provided dates. |
Acciones en circulación de empresas similares o competidores
| Empresa |
Acciones en circulación |
Diferencia |
País |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
0.00 |
-
|
BE
|
|
|
- |
-
|
KR
|
